CEO INVESTOR CONFERENCE bio.org/CEO • #BIOCEO17 Audience Demographics Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies. February 13-14, 2017 • The Waldorf Astoria New York 86% 86% of attendees are VP or C-Level Director Other VP C-level 86% 4% 10% 76% 10% Oncology: 29% Platform Discovery: 2% Infectious Diseases: 2% CNS: 13% Other: 10% Orphan/Rare Diseases: 10% Autoimmune Inflammation: 7% Devices & Drug Delivery: 4% Metabolic Diseases: 4% Ophthalmology: 4% Multiple: 4% Regenerative Medicine: 3% Cardiovascular: 3% Gastrointestinal: 3% Diagnostics: 2% Breakdown by Therapeutic Focus: Job Profile: 82% 82% of all companies attending are biopharma Companies Profile: Attendees: 1,400+ One-on-One Meetings: 2,500+ Registered Investors: 650 Company Presentations: 190 Expert Speakers: 58 < $50M: 36% $500M: 4% $100M-250M: 32% $50M-100M: 22% $250M-500M: 6% Breakdown by Market Cap:
4
Embed
Audience Demographics - Biotechnology Innovation … Prosepctus_no...developments affecting the industry. Evaluate fresh investment opportunities including compatible, complementary,
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
CEO INVESTORCONFERENCE
bio.org/CEO • #BIOCEO17
Audience Demographics
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies.
February 13-14, 2017 • The Waldorf Astoria New York
February 13-14, 2017 • The Waldorf Astoria New York
CEO INVESTORCONFERENCE
2
Past Fireside Chat Speakers
Samuel D. IsalyManaging Partner, OrbiMed Advisors
John F. Milligan, PhDPresident and Chief Operating Officer, Gilead Sciences
Christi ShawUS Country Head, President of Novartis Corporation & President of Novartis Pharmaceuticals Corporation
George A. Scangos, PhDChief Executive Officer, Biogen
Charles E. SchumerUnited States Senator for New York (D)
Event Attributes and Opportunities
▲ Experience the largest, unbiased forum where institutional investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry.
▲ Hear Washington’s perspective on policy and other timely developments affecting the industry.
▲ Evaluate fresh investment opportunities including compatible, complementary, and competitive companies.
▲ Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.
▲ Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2017.
▲ Gain access to BIO One-on-One Partnering™ for scouting potential investments and deal partners, optimizing your time at the event.
▲ Unique platform for your company to highlight accomplishments and discuss upcoming milestones. Approximately 190 companies will be chosen based on a selection process evaluating a company’s pipeline and R&D activities.
▲ Get the pulse of the current and proposed investment trends in biotechnology.
▲ Network with peers, investors, and potential partners attending the conference and our exclusive receptions.
Advisory CommitteeJohn Chambers, Vice-Chairman and Head of Healthcare Investment Banking, ROTH Capital PartnersBarbara J. Dalton, PhD, Vice President, Venture Capital, Pfizer Inc.Linda S. Grais, MD, President and Chief Executive Officer, Ocera TherapeuticsBrian Hagerty, Senior Director, Head of Healthcare Capital Markets, New York Stock ExchangeNouhad Husseini, Vice President, Business Development, Regeneron Pharmaceuticals, Inc.Michael King, Managing Director and Senior Research Analyst, JMP SecuritiesJonathan Leff, Partner, Deerfield ManagementMichael Mirsky, Managing Director, Investment Banking, H.C. WainwrightTimothy P. O’Connor, PhD, Executive Vice President, The Rockefeller UniversityJason Park, Principal, Flagship VenturesDennis J. Purcell, Founder and Senior Advisor, Aisling CapitalCarlo Rizzuto, PhD, Partner, Versant VenturesMatthew Roden, PhD, Vice President and Head of Strategic Corporate Development, Bristol-Myers SquibbStephen Sands, Vice Chairman Investment Banking and Chairman Global Healthcare Group, LazardRajeev Shah, Managing Director & Portfolio Manager, RA CapitalNathan Tinker, PhD, Executive Director, NewYorkBIO